The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Open accessAbstract
BACKGROUND: Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. METHODS: In this 6-month randomized, multicenter trial, patients with type 1 diabetes were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter), as measured by continuous glucose monitoring. RESULTS: A total of 168 patients underwent randomization; 112 were assigned to the closed-loop group, and 56 were assigned to the control group. The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%. All 168 patients completed the trial. The mean (±SD) percentage of time that the glucose level was within the target range increased in the closed-loop group from 61±17% at baseline to 71±12% during the 6 months and remained unchanged at 59±14% in the control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14; P<0.001). The results with regard to the main secondary outcomes (percentage of time that the glucose level was >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that the glucose level was <70 mg per deciliter or <54 mg per deciliter [3.0 mmol per liter]) all met the prespecified hierarchical criterion for significance, favoring the closed-loop system. The mean difference (closed loop minus control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P<0.001). The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 percentage points (95% CI, -0.53 to -0.13; P = 0.001). In the closed-loop group, the median percentage of time that the system was in closed-loop mode was 90% over 6 months. No serious hypoglycemic events occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group. CONCLUSIONS: In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, NCT03563313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The largest trial with this class in T1D was with liraglutide, which showed a reduction of A1C of 0.4% with the highest 1.8 mg dose in addition to a 5 kg weight loss and insulin dose reductions.1177”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the introduction of CGM devices that alarm with low blood glucose concentrations and semiautomated pumps that suspend insulin infusion as glucose concentrations decrease have facilitated achieving target HbA 1c levels with less risk for hypoglycemia (332).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [332]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hybrid closedloop systems are the most effective means of maintaining glucose in the normal range in people with type 1 diabetes (90,91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of insulin analog regimens are associated with less hypoglycemia, while hybrid closed-loop systems result in both improvement in TIR and reduction in TBR (91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These prestigious publications reported pivotal trials of the commercial descendant of DiAs-a new AID system (Control-IQ by Tandem Diabetes Care)-in different age groups: 14 years old and older, 132 6 to 13 years old, 133 and 2 to 6 years old.134”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“This large-scale study and its continuation with young children ages 2 to 6 years old completed several clinical protocols, three of which were published in the New England Journal of Medicine.[132][133][134]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“In particular, glucose time in range (70 -180 mg/dl [3.9 -10.0 mmol/l]) and time in hypoglycemia ( < 70 mg/dl [3.9 mmol/l] and < 54 mg/dl [3.0 mmol/l]) have been used as outcomes for clinical trials 259,260 and have been endorsed as appropriate metrics for clinical care. 229”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [260]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that an AID hybrid closed-loop system is superior to AID sensor-augmented pump therapy for increased percentage of time in range and reduction of hypoglycemia (34,35).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“HbA 1c , TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90,91).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although this agent was more effective with those participants still producing endogenous insulin, the added hypoglycemia and ketosis noted has resulted in no attempt for FDA approval in T1D.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Experimental — accuracy not yet measuredIn the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Kleinman, L. C., & Norton, E. C. (2008) · Health Services Research · doi:10.1111/j.1475-6773.2008.00900.x · Cited by 287
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 999
March, C. A., Hill, A., Kazmerski, T. M., Siminerio, L. M., Switzer, G. E., Miller, E. P., & Libman, I. M. (2023) · Pediatric Diabetes · doi:10.1155/2023/2162900 · Cited by 10
One Size Fits All Versus Individualized Medicine in Type 1 Diabetes Management
Midyett, L. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0109 · Cited by 14
TELLEZ, S. E., Hornung, L. N., Abu‐El‐Haija, M. A., & Elder, D. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093319 · Cited by 9
Simulation-driven optimization of insulin therapy profiles in a commercial hybrid closed-loop system
C., J. L. D., Villa-Tamayo, M. F., Moscoso-Vásquez, M., & Colmegna, P. H. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107830 · Cited by 9
Ferreira, R. O. M., Trevisan, T., Pasqualotto, E., Schmidt, P., Pedrotti, M., Watanabe, J. M. F., & van de Sande‐Lee, S. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0280 · Cited by 12
Barth, C.-M., Bernard, J., & Huang, E. M. (2024) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3613904.3642234 · Cited by 15
Scidà, G., Corrado, A., Abuqwider, J., Lupoli, R., Rainone, C., Pepa, G. D., Masulli, M., Annuzzi, G., & Bozzetto, L. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241256475 · Cited by 9
Gera, S., Rearson, A., Baker, G., Douvas, J. L., Alicea-Trelles, N., Gallop, R., Meighan, S. S., & Marks, B. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf006 · Cited by 9
Vallivaara, H., Leppänen, H. A., Mustonen, J., Saari, A., Martikainen, J. A., & Rintamäki, R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16520 · Cited by 9
Fang, M., Wang, D., Rebholz, C. M., Echouffo-Tcheugui, J. B., Tang, O., Wang, N., MITCHELL, C. M., Pilla, S. J., Appel, L. J., & Selvin, E. (2025) · Nature Medicine · doi:10.1038/s41591-025-03823-3 · Cited by 10
Exploring dynamical properties of a Type 1 diabetes model using sensitivity approaches
Ali, H. A., Daneshkhah, A., Boutayeb, A., Malunguza, N. J., & Mukandavire, Z. (2022) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2022.05.008 · Cited by 9
Grand challenges in mathematical biology: Integrating multi-scale modeling and data
Eftimie, R. (2022) · Frontiers in Applied Mathematics and Statistics · doi:10.3389/fams.2022.1010622 · Cited by 9
Colmegna, P. H., C., J. L. D., Garcia‐Tirado, J., DeBoer, M. D., & Breton, M. D. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221140401 · Cited by 9
Lin, Y. K., Agni, A., Chuisano, S. A., Fetters, M. D., Funnell, M. M., Pop‐Busui, R., & DeJonckheere, M. J. (2023) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106231168859 · Cited by 10
Garcia‐Tirado, J., Villard, O., Hall, M., Bisio, A., & Gonder-Frederick, L. A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0197 · Cited by 9
New therapies towards a better glycemic control in youths with type 1 diabetes
Cardona‐Hernandez, R., Dovč, K., Biester, T., Ekhlaspour, L., Macedoni, M., Tauschmann, M., & Mameli, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106882 · Cited by 12
Self-citationJancev, M., Snoek, F. J., Frederix, G., Knottnerus, H., Blauw, H., Witkop, M., Moons, K. G. M., van Bon, A. C., DeVries, J. H., Serné, E. H., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-074984 · Cited by 9
A Nutritional Approach to Optimizing Pump Therapy in Type 1 Diabetes Mellitus
Gitsi, E., Livadas, S., Angelopoulos, N., Paparodis, R. D., Raftopoulou, M., & Argyrakopoulou, G. (2023) · Nutrients · doi:10.3390/nu15234897 · Cited by 11
Fresa, R., Bitterman, O., Cavallaro, V., Filippi, M. D., Dimarzo, D., Mosca, C., Nappi, F., Rispoli, M., & Napoli, A. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02315-z · Cited by 10
Liao, B., Chen, Y., Chigutsa, F. B., & de Oliveira, C. P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14370 · Cited by 9
Fantasia, K. L., Demers, L., Steenkamp, D., & Modzelewski, K. L. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221077132 · Cited by 8
Zuijdwijk, C., Courtney, J. M., Mitsakakis, N., Hayawi, L. M., Sutherland, S., Newhook, D., Ahmet, A. H., Goldbloom, E. B., Khatchadourian, K., & Lawrence, S. E. (2023) · Pediatric Diabetes · doi:10.1155/2023/5106107 · Cited by 9
Young, G. M., Jacobs, P. G., Tyler, N. S., Nguyen, T.-T. P., Castle, J. R., Wilson, L. M., Branigan, D. L., Gabo, V. B., Guillot, F. H., Riddell, M. C., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00298.2022 · Cited by 8
Tandon, A., Bhowmik, E., Ali, Z., Tripathi, S., Ajitha, B. K., Chen, Y., Dabadghao, P., Sudhanshu, S., & Bhatia, V. (2023) · Nutrition · doi:10.1016/j.nut.2023.112318 · Cited by 8
Steenkamp, D., Brouillard, E., Aia, C., Fantasia, K. L., Sullivan, C. A. W., Atakov-Castillo, A., & Wolpert, H. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.04.001 · Cited by 11
Kalita, D., & Mirza, K. B. (2025) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2025.3530461 · Cited by 9
Karakus, K. E., Aktürk, H. K., Snell‐Bergeon, J. K., & Shah, V. N. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251318740 · Cited by 8
Closed-loop therapy: recent advancements and potential predictors of glycemic outcomes
Royston, C., Hovorka, R., & Boughton, C. K. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2492363 · Cited by 11
Evolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems
Bergenstal, R. M., Heller, A., Breton, M. D., Vigersky, R. A., Brown, S. A., Forlenza, G. P., Sherr, J. L., Hovorka, R., Russell, S. J., Damiano, E. R., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251342239 · Cited by 9
Self-citationSecuring automated insulin delivery systems: A review of security threats and protective strategies
Niu, Y., & Lam, S.-K. (2025) · Computers & Security · doi:10.1016/j.cose.2025.104733 · Cited by 10
Smarter Modeling to Enable a Smarter Insulin
Taylor, S. I., & DiMarchi, R. D. (2020) · Diabetes · doi:10.2337/dbi20-0011 · Cited by 8
Deshpande, S., WEINZIMER, S. A., Gibbons, K., Nally, L. M., Weyman, K., CARRIA, L. R., Zgorski, M., Laffel, L. M., Doyle, F. J., & Dassau, E. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221116384 · Cited by 10
Self-citationReprogramming—Evolving Path to Functional Surrogate β-Cells
Kalo, E., Read, S. A., & Ahlenstiel, G. (2022) · Cells · doi:10.3390/cells11182813 · Cited by 8
Navas-Moreno, V., Sebastián‐Valles, F., Sampedro-Nuñez, M. A., Vargas, M. L., Marazuela, M., & Martín, J. A. A. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2023.06.004 · Cited by 8
Jafar, A., & Pasqua, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15463 · Cited by 10
Christensen, M. B., Ranjan, A. G., Rytter, K., McCarthy, O. M., Schmidt, S., & Nørgaard, K. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241242399 · Cited by 9
Continuous glucose monitoring reduces pubertal hyperglycemia of type 1 diabetes
Nwosu, B. U., Yeasmin, S., Ayyoub, S., Rupendu, S., Villalobos-Ortiz, T. R., Jasmin, G., Parajuli, S., Zahedi, B., Zitek‐Morrison, E., Alonso, L. C., et al. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0057 · Cited by 9
Weekly Insulin Becoming a Reality
Skyler, J. S. (2021) · Diabetes Care · doi:10.2337/dci21-0011 · Cited by 8
Decision Support Systems and Closed‐Loop
Nimri, R., Phillip, M., & Kovatchev, B. P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.2504 · Cited by 9
Self-citationQuirós, C., Alonso-Carril, N., Rodriguez-Rodríguez, S., Barahona, M. J., Orois, A., Simó-Servat, A., Ramos, M., & Perea, V. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.10.003 · Cited by 8
Quirós, C., Alonso-Carril, N., Rodriguez-Rodríguez, S., Barahona, M. J., Orois, A., Simó-Servat, A., Ramos, M., & Perea, V. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.10.005 · Cited by 8
School-Based Diabetes Care: A National Survey of U.S. Pediatric Diabetes Providers
March, C. A., Siminerio, L. M., Kazmerski, T. M., Albanese-O’Neill, A., Miller, E. P., & Libman, I. M. (2023) · Pediatric Diabetes · doi:10.1155/2023/4313875 · Cited by 8
Berget, C., & Wyckoff, L. (2020) · NASN School Nurse · doi:10.1177/1942602x20928914 · Cited by 8
Charting the next century of insulin replacement with cell and gene therapies
Lau, H. H., Gan, S. U., Lickert, H., Shapiro, A. M. J., Lee, K., & Teo, A. K. K. (2021) · Med · doi:10.1016/j.medj.2021.09.001 · Cited by 8
Schmidt, S., Madsen, K. P., Pedersen-Bjergaard, U., Rytter, K., Hommel, E., Cleal, B., Willaing, I., Andersen, H. U., & Nørgaard, K. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02081-4 · Cited by 5
Daytime hypoglycemic episodes during the use of an advanced hybrid closed loop system
Rossi, A., Montefusco, L. B., Reseghetti, E., Pastore, I., Rossi, G., Usuelli, V., Loretelli, C., Boci, D., Nasr, M. B., D’Addio, F., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111011 · Cited by 7
Watso, J. C., Robinson, A. T., Singar, S., Cuba, J. N., & Koutnik, A. P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00694.2023 · Cited by 8
Gargouri, I., Charfi, H., Belabed, W., Outenah, C., Pochat, A., Touimer, M., Huynh, P., Petit, C., Lejeune, M., Eroukhmanoff, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16118 · Cited by 7
Berget, C., Annan, F., Biester, T., Choudhary, P., Forlenza, G. P., Peters, A. L., Renard, É., & Deiss, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16321 · Cited by 8
Self-citationAnandhakrishnan, A., Pender, S., Johnston, T., Hyslop, R., Liu, Y., Kariyawasam, D., Brackenridge, A., Karalliedde, J. J., & Hussain, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16553 · Cited by 8
Joubert, M., Meyer, L., Bekka, S., Rakotoarisoa, L., Scheyer, N., Dreves, B., & Guerci, B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70122 · Cited by 7
Insurance Coverage for Emerging Diabetes Technologies: Payers' Perspective
Nolan, T., & Frazzitta, M. A. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0262 · Cited by 6
Efficacy of Control-IQ Technology in a General Endocrine Clinic
Usoh, C. O., Price, C. E., Johnson, C. P., Speiser, J. L., & Aloi, J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.010 · Cited by 7
Impaired awareness of hypoglycaemia
Amiel, S. A. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.358 · Cited by 7
Monlezun, D. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18906-7.00009-x · Cited by 7
March, C. A., Nanni, M., Lutz, J. M., Kavanaugh, M., Jeong, K., Siminerio, L. M., Rothenberger, S. D., Miller, E. P., & Libman, I. M. (2023) · Pediatric Diabetes · doi:10.1155/2023/8176606 · Cited by 8
Alwan, H., Ware, J., Boughton, C. K., Wilinska, M. E., Allen, J. M., Lakshman, R., Nwokolo, M., Hartnell, S., Bally, L., de Beaufort, C. E., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0061 · Cited by 7
Glucose Rate-of-Change and Insulin-on-Board Jointly Weighted Zone Model Predictive Control
Deshpande, S., Doyle, F. J., & Dassau, E. (2023) · IEEE Transactions on Control Systems Technology · doi:10.1109/tcst.2023.3291573 · Cited by 7
Self-citationRenard, É., Tubiana‐Rufi, N., Chaillous, L., Bonnemaison, É., Hanaire, H. P., Bismuth, É., Joubert, M., Coutant, R., Schaepelynck, P., Beltrand, J., et al. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.04.002 · Cited by 7
Wang, Y.-Y., Ying, H., Fang, T. I. A. N., Qian, X., & Zhou, Z.-F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308202 · Cited by 7
Attention Networks for Personalized Mealtime Insulin Dosing in People with Type 1 Diabetes
Fathi, A. E., Pryor, E. C., & Breton, M. D. (2024) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2024.11.044 · Cited by 7
Pavan, J., Cobry, E. C., Reed, Z. W., Villa-Tamayo, M. F., C., J. L. D., DeBoer, M. D., Schoelwer, M. J., Jost, E., KINGMAN, R. S., Holmes, V. F., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0650 · Cited by 8
Self-citationCastillo, A., Pryor, E. C., Fathi, A. E., Kovatchev, B. P., & Breton, M. D. (2025) · IEEE Transactions on Cybernetics · doi:10.1109/tcyb.2025.3562032 · Cited by 7
Self-citationOne-year evaluation of automated insulin delivery systems in adults with type 1 diabetes
Pujante, P., García, A. V., Villa-Fernández, E., García‐Villarino, M., González‐Vidal, T., Díaz-Naya, L., Gutiérrez-Buey, G., Veiguela, B., Rivas‐Otero, D., Torre, E. L. M., et al. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1596188 · Cited by 6
Feasibility of large experimental animal models in testing novel therapeutic strategies for diabetes
Nagaya, M., Hasegawa, K., Uchikura, A., Nakano, K., Watanabe, M., Umeyama, K., Matsunari, H., Osafune, K., Kobayashi, E., Nakauchi, H., et al. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.306 · Cited by 7
Automated Insulin Delivery Systems: Today, Tomorrow and User Requirements
Giménez, M., Conget, I., & Oliver, N. S. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211029937 · Cited by 7
A centennial review of discoveries and advances in diabetes: Children and youth
Mistry, S., Tonyushkina, K. N., Benavides, V. C., Choudhary, A., Huerta‐Saenz, L., Patel, N. S., Mahmud, F. H., Libman, I. M., & Sperling, M. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13392 · Cited by 12
Schoemaker, M., Martensson, A., Mader, J. K., Nørgaard, K., Freckmann, G., Benhamou, P., Diem, P., & Heinemann, L. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231203237 · Cited by 8
Latest Advancements in Artificial Intelligence-Enabled Technologies in Treating Type 1 Diabetes
Qian, F., & Schumacher, P. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820949940 · Cited by 7
Pereira, J. P. A., Brandão, A. A. F., Bevilacqua, J. D. S., & Corrêa‐Giannella, M. L. (2022) · Applied Sciences · doi:10.3390/app12199641 · Cited by 7
Diabetes Technology Meeting 2020
Shang, T., Zhang, J. Y., Bequette, B. W., Raymond, J. K., Coté, G. L., Sherr, J. L., Castle, J. R., Pickup, J. C., Pavlovic, Y., Espinoza, J., et al. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211016480 · Cited by 8
Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Hernández, J. A. Z., Castillo-Castro, C., & Rodríguez-Gutiérrez, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmc1915995 · Cited by 7
Rosselot, C., Alvarsson, A., Wang, P., Li, Y., Beliard, K., Lu, G., Li, R., Liu, H., Gillespie, V., Tzavaras, N., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.24.220244 · Cited by 7
Steenkamp, D. W., Cheney, M. C., Ju, Z., Rodbard, D., & Wolpert, H. A. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad038 · Cited by 7
Automated Insulin Delivery for Type 1 Diabetes: Present and Future
Akcan, T., Lee, M. Y., Needleman, L., & Lal, R. (2025) · Diabetes Spectrum · doi:10.2337/dsi25-0003 · Cited by 6
Resi, V., Bianchi, C., Burlina, S., Grancini, V., Manicardi, E., Masulli, M., Scarpitta, A. M., Sorice, G. P., & Fresa, R. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02592-2 · Cited by 7
Wilkinson, T., de Bock, M. I., Meier, R. A., Hurd, S., Sasson-Katchalski, R., Trahan, A. C., Rueda, J. R., Sherer, N. A., Stephens, M., Meyer, B., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251389966 · Cited by 6
Self-citationCinar, B., van den Boom, L., & Maleshkova, M. (2025) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2025.101723 · Cited by 6
Moscoso-Vásquez, M., Ekhlaspour, L., Brown, S. A., DeBoer, M. D., Berget, C., Cobry, E. C., Wadwa, R. P., Capodanno, G., Cengiz, E., Wong, J. C., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1526 · Cited by 8
Self-citationWilkinson, T., Nanayakkara, N., Burren, D., Jenkins, A., Williman, J. A., Keesing, C., Boyle, E., Elghattis, Y., Bennett, A., Gunn, T. C., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261423558 · Cited by 6
Sarwar, M. A., Damaševičius, R., Belousovienė, E., & Maskeliūnas, R. (2026) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2026.103409 · Cited by 6
Tatulashvili, S., Dreves, B., Meyer, L., Cosson, E., & Joubert, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111592 · Cited by 8
Baxter, F., Baillie, N., Dover, A. R., Stimson, R. H., Gibb, F. W., & Forbes, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297601 · Cited by 7
Monnier, L., Colette, C., Renard, É., Benhamou, P., Aouinti, S., Molinari, N., & Owens, D. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101589 · Cited by 8
Brown, S. A., Laffel, L. M., Aktürk, H. K., Forlenza, G. P., Shah, V. N., Wadwa, R. P., Cobry, E. C., ISGANAITIS, E. M., Schoelwer, M. J., Lu, V. M., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0501 · Cited by 6
Self-citationTransitioning between automated insulin delivery systems: A focus on personalisation
Beato-Víbora, P. I., Chico, A. I., Moreno-Fernández, J., Azriel, S., Nattero‐Chávez, L., Mora, M. R. V., Alonso-Carril, N., Simó‐Servat, O., Aguilera, E., Reyes, L., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112070 · Cited by 8
Registration and Real-Life Studies on Automated Insulin Delivery Systems
Aktürk, H. K., Brown, S. A., Beck, R. W., Sherr, J. L., Bergenstal, R. M., Kovatchev, B. P., Vigersky, R. A., Breton, M. D., Hovorka, R., Klonoff, D. C., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251334993 · Cited by 6
Self-citationRegistration and Real-Life Studies on Automated Insulin Delivery Systems
Aktürk, H. K., Brown, S. A., Beck, R. W., Sherr, J. L., Bergenstal, R. M., Kovatchev, B. P., Vigersky, R. A., Breton, M. D., Hovorka, R., Klonoff, D. C., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0130 · Cited by 6
Self-citationThe Evolution of Insulin Administration in Type 1 Diabetes
Pinnaro, C. T., & Tansey, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115021 · Cited by 7
Kaur, R. J., Deshpande, S., Pinsker, J. E., Gilliam, W. P., MCCRADY-SPITZER, S. K., Zaniletti, I., Desjardins, D., Church, M. M., Doyle, F. J., Kremers, W. K., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0436 · Cited by 6
Self-citationde Portu, S., Vorrink, L., Ré, R., Shin, J., Castañeda, J., Habteab, A., & Cohen, O. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-050635 · Cited by 6
Kaur, R. J., Smith, B. H., Özaslan, B., Pinsker, J. E., Trinidad, M. C., O’Malley, G., Desjardins, D., CASTORINO, K. N., Levister, C. M., Reid, C. L., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0479 · Cited by 6
Self-citationA Review on Newer Interventions for the Prevention of Diabetic Foot Disease
Tekale, S., Varma, A. R., Tekale, S., & Kumbhare, U. (2022) · Cureus · doi:10.7759/cureus.30591 · Cited by 7
Glycaemic control and novel technology management strategies in pregestational diabetes mellitus
Newman, C., Ero, A., & Dunne, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1109825 · Cited by 6
DeBoer, M. D., Valdez, R. S., Corbett, J. P., Krauthause, K., WAKEMAN, C. A., Luke, A. S., Oliveri, M. C., Cherñavvsky, D. R., & Patek, S. D. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01401-9 · Cited by 6
Mesa, A., Beneyto, A., José, J., Viaplana, J., Bondía, J., Vehı́, J., Conget, I., & Giménez, M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110956 · Cited by 7
Hoppe, J. E., Sjoberg, J., Hong, G., Poch, K. R., Zemanick, E. T., Thee, S. A., Edmondson, C. L., Patel, D. R., Sathe, M., Borowitz, D., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.02.011 · Cited by 7
Barasch, N., Romig, M. C., Demko, Z. O., Dwyer, C., Dietz, A. S., Rosen, M. A., Griffiths, S., Ravitz, A., Pronovost, P. J., & Sapirstein, A. (2019) · Journal of Patient Safety and Risk Management · doi:10.1177/2516043519893228 · Cited by 6
Carral, F., Tomé, M., Alba, J. J. F., Zaldivar, A. P., Expósito, C., Jiménez, A. I., García, C., & Ayala, C. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.07.009 · Cited by 6
In Silico Testing of a Control Algorithm for a Personalized Insulin Therapy System
Витольдович, П. К., Bazaev, N. A., & Litinskaia, E. L. (2021) · IEEE Conference of Russian Young Researchers in Electrical and Electronic Engineering · doi:10.1109/elconrus51938.2021.9396210 · Cited by 6
Metadata
- Authors
- Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., Dassau, E., Doyle, F. J., Anderson, S. M., Church, M. M., Dadlani, V., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Kollman, C., & Beck, R. W.
- Affiliations
- Sansum Diabetes Research Institute (US)
- Mayo Clinic (US)
- Joslin Diabetes Center (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-31
- Volume
- 381
- Issue
- 18
- Pages
- 1707-1717
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7076915
- OpenAlex
- W2981310284
- Semantic Scholar
- a8aee7f3c717498afd65ea39bd87dd1c1ea5d693
- Cited by
- 1,030
- References
- 17
- Citations by year
- 2026: 128 · 2025: 134 · 2024: 140 · 2023: 180 · 2022: 158 · 2021: 156 · 2020: 125 · 2019: 8
- FWCI
- 90.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4 DK108483)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, sensor-augmented pump, continuous glucose monitoring, glycemic control, HbA1c, hypoglycemia, hyperglycemia, insulin pump therapy, glycemic variability, HbA1c reduction, hypoglycemia risk reduction, HbA1c thresholds, hypoglycemia risk
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Pancreas, Artificial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
